|
Llombart-Cussac A, Perez-Garcia JM, Ruiz Borrego M, Tolosa P, Blanch S, Fernandez-Ortega A, Urruticoechea A, Blancas I, Saura C, Rojas B, Bermejo B, Ponce Lorenzo J, Gion M, Cortez-Castedo P, Llabres E, Galve E, Cueva JF, Lopez A, Alonso-Romero JL, Gonzalez-Santiago S, Martinez de Duenas E, Ciruelos E, Martrat G, Gener P, Alcala-Lopez D, Sampayo-Cordero M, Gomez-Peralta F, Cortes J. Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2024 Apr 11;71:102520. doi: 10.1016/j.eclinm.2024.102520. eCollection 2024 May. PubMed PMID: 38638399; PubMed Central PMCID: PMC11024566.
AÑO: 2024; IF: 10.0
|
38638399
|
Li X., Zhang Y., Zhu C., Xu W., Hu X., Martínez D.A.S., Romero J.L.A., Yan M., Dai Y., Wang H. Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer. BMC Women S Health. December 2024. 24. 10.1186/s12905-023-02871-6
AÑO: 2024; IF: 2.7
|
|
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Levy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. PubMed PMID: 39282896.
AÑO: 2024; IF: 78.5
|
|
Márquez-Rodas I., Álvarez A., Arance A., Valduvieco I., Berciano-Guerrero M.Á., Delgado R., Soria A., Campos F.L., Sánchez P., Romero J.L., Martin-Liberal J., Lucas A., Díaz-Beveridge R., Conde-Moreno A.J., De La Gala M.D.C.Á., García-Castaño A., Prada P.J., Cao M.G., Puertas E., Vidal J., Foro P., De La Rosa C.A., Corona J.A., Cerezuela-Fuentes P., López P., Luna P., Aymar N., Puértolas T., Sanagustín P., Berrocal A. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study). Neuro Oncology. 1 November 2024. 26:2074-2083. 10.1093/neuonc/noae116
AÑO: 2024; IF: 13.4
|
|
Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Aunon P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, Perez-Moreno PD, Lopez-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA; coopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023 Sep;24(9):1029-1041. doi: 10.1016/S1470-2045(23)00268-1. Erratum In: Lancet Oncol. 2023 Nov;24(11):e425. doi: 10.1016/S1470-2045(23)00482-5. PubMed PMID: 37657462.
AÑO: 2023; IF: 41.6
|